Tenet Healthcare (THC) Tops Q4 EPS by 23c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Mid-Point Views Abvoe Consensus, Provides Q1 EPS/Revenue Outlook

Go back to Tenet Healthcare (THC) Tops Q4 EPS by 23c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Mid-Point Views Abvoe Consensus, Provides Q1 EPS/Revenue Outlook

Tenet Healthcare (THC) PT Raised to $29 at RBC Capital

February 27, 2019 7:21 AM EST

RBC Capital analyst Frank Morgan raised the price target on Tenet Healthcare (NYSE: THC) to $29.00 (from $26.00) while maintaining a Sector Perform rating.

... More

Tenet Healthcare (THC) PT Raised to $30 at SunTrust

February 27, 2019 2:47 AM EST

SunTrust analyst David MacDonald raised the price target on Tenet Healthcare (NYSE: THC) to $30.00 (from $23.00) while maintaining a Hold rating.

... More

Tenet Healthcare (THC) PT Raised to $30 at Baird

February 26, 2019 8:13 AM EST

Baird analyst Matthew Gillmor raised the price target on Tenet Healthcare (NYSE: THC) to $30.00 (from $25.00) while maintaining a Neutral rating following Q4.

... More